Cargando…

Diagnostic Value of Interferon-Gamma Release Assays for Tuberculosis in the Immunocompromised Population

Interferon-gamma release assays (IGRAs) are widely used in the diagnosis of Mycobacterium tuberculosis (M. tuberculosis) infection by detecting interferon-γ released by previously sensitized T-cells in-vitro. Currently, there are two assays based on either enzyme-linked immunosorbent assay (ELISA) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ying, Wang, Hong-Jiao, Hu, Wei-Lin, Bai, Guan-Nan, Hua, Chun-Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871457/
https://www.ncbi.nlm.nih.gov/pubmed/35204544
http://dx.doi.org/10.3390/diagnostics12020453
_version_ 1784657000878047232
author Yang, Ying
Wang, Hong-Jiao
Hu, Wei-Lin
Bai, Guan-Nan
Hua, Chun-Zhen
author_facet Yang, Ying
Wang, Hong-Jiao
Hu, Wei-Lin
Bai, Guan-Nan
Hua, Chun-Zhen
author_sort Yang, Ying
collection PubMed
description Interferon-gamma release assays (IGRAs) are widely used in the diagnosis of Mycobacterium tuberculosis (M. tuberculosis) infection by detecting interferon-γ released by previously sensitized T-cells in-vitro. Currently, there are two assays based on either enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunospot (ELISPOT) technology, with several generations of products available. The diagnostic value of IGRAs in the immunocompromised population is significantly different from that in the immunocompetent population because their results are strongly affected by the host immune function. Both physiological and pathological factors can lead to an immunocompromised situation. We summarized the diagnostic value and clinical recommendations of IGRAs for different immunocompromised populations, including peoplewith physiological factors (pregnant and puerperal women, children, and older people), as well as people with pathological factors (solid organ transplantation recipients, combination with human immunodeficiency virus infection, diabetes mellitus, end-stage renal disease, end-stage liver disease, and chronic immune-mediated inflammatory diseases). Though the performance of IGRAs is not perfect and often requires a combination with other diagnostic strategies, it still has some value in the immunocompromised population. Hopefully, the newly developed IGRAs could better target this population.
format Online
Article
Text
id pubmed-8871457
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88714572022-02-25 Diagnostic Value of Interferon-Gamma Release Assays for Tuberculosis in the Immunocompromised Population Yang, Ying Wang, Hong-Jiao Hu, Wei-Lin Bai, Guan-Nan Hua, Chun-Zhen Diagnostics (Basel) Review Interferon-gamma release assays (IGRAs) are widely used in the diagnosis of Mycobacterium tuberculosis (M. tuberculosis) infection by detecting interferon-γ released by previously sensitized T-cells in-vitro. Currently, there are two assays based on either enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunospot (ELISPOT) technology, with several generations of products available. The diagnostic value of IGRAs in the immunocompromised population is significantly different from that in the immunocompetent population because their results are strongly affected by the host immune function. Both physiological and pathological factors can lead to an immunocompromised situation. We summarized the diagnostic value and clinical recommendations of IGRAs for different immunocompromised populations, including peoplewith physiological factors (pregnant and puerperal women, children, and older people), as well as people with pathological factors (solid organ transplantation recipients, combination with human immunodeficiency virus infection, diabetes mellitus, end-stage renal disease, end-stage liver disease, and chronic immune-mediated inflammatory diseases). Though the performance of IGRAs is not perfect and often requires a combination with other diagnostic strategies, it still has some value in the immunocompromised population. Hopefully, the newly developed IGRAs could better target this population. MDPI 2022-02-10 /pmc/articles/PMC8871457/ /pubmed/35204544 http://dx.doi.org/10.3390/diagnostics12020453 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yang, Ying
Wang, Hong-Jiao
Hu, Wei-Lin
Bai, Guan-Nan
Hua, Chun-Zhen
Diagnostic Value of Interferon-Gamma Release Assays for Tuberculosis in the Immunocompromised Population
title Diagnostic Value of Interferon-Gamma Release Assays for Tuberculosis in the Immunocompromised Population
title_full Diagnostic Value of Interferon-Gamma Release Assays for Tuberculosis in the Immunocompromised Population
title_fullStr Diagnostic Value of Interferon-Gamma Release Assays for Tuberculosis in the Immunocompromised Population
title_full_unstemmed Diagnostic Value of Interferon-Gamma Release Assays for Tuberculosis in the Immunocompromised Population
title_short Diagnostic Value of Interferon-Gamma Release Assays for Tuberculosis in the Immunocompromised Population
title_sort diagnostic value of interferon-gamma release assays for tuberculosis in the immunocompromised population
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871457/
https://www.ncbi.nlm.nih.gov/pubmed/35204544
http://dx.doi.org/10.3390/diagnostics12020453
work_keys_str_mv AT yangying diagnosticvalueofinterferongammareleaseassaysfortuberculosisintheimmunocompromisedpopulation
AT wanghongjiao diagnosticvalueofinterferongammareleaseassaysfortuberculosisintheimmunocompromisedpopulation
AT huweilin diagnosticvalueofinterferongammareleaseassaysfortuberculosisintheimmunocompromisedpopulation
AT baiguannan diagnosticvalueofinterferongammareleaseassaysfortuberculosisintheimmunocompromisedpopulation
AT huachunzhen diagnosticvalueofinterferongammareleaseassaysfortuberculosisintheimmunocompromisedpopulation